WuXi Biologics (Cayman) Inc.
2269
Peringkat dalam Saham
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Harga Saham
$5.77
Kapitalisasi Pasar
$23.74B
Perubahan (1 hari)
-8.38%
Perubahan (1 tahun)
25.13%
Negara
CN
Perdagangan WuXi Biologics (Cayman) Inc. (2269)
Kategori
Healthcare
Pendapatan untuk WuXi Biologics (Cayman) Inc. (2269)
Pendapatan pada Oct 2026 TTM: 0
Menurut laporan keuangan terbaru dari WuXi Biologics (Cayman) Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan WuXi Biologics (Cayman) Inc. dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2025 | $3.11B | 21.73% |
| 2024 | $2.56B | 6.32% |
| 2023 | $2.41B | 8.72% |
| 2022 | $2.21B | 36.72% |
| 2021 | $1.62B | 88.45% |
| 2020 | $859.12M | 50.17% |
| 2019 | $572.10M | 55.27% |
| 2018 | $368.45M | 48.08% |
| 2017 | $248.81M | 74.67% |
| 2016 | $142.45M | 66.06% |
| 2015 | $85.78M | 60.11% |
| 2014 | $53.58M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
